Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the U.S. FDA has approved RAPAFLO (silodosin), the company's new alpha blocker for the treatment of the signs and symptoms of BPH.
The details can be read here.
No comments:
Post a Comment